Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 343

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 343
---
 non -votewill have no effect on the Adjournment Proposal. The Closing is not conditioned upon the approval of the Adjournment Proposal. Recommendation of the APx Board THE APx BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS
VOTE “FOR” THE APPROVAL OF THE ADJOURNMENT PROPOSAL. 175 Business of the Company and Certain Information About the Company References in this section to “we”, “our”, “us”, the “Company” or “OmnigenicsAI” generally refer to OmnigenicsAI Corp and “Combined Company” refers to OmnigenicsAI Corp and its subsidiaries after the Closing of the Transactions. Incorporation OmnigenicsAI Corp is a Cayman Islands exempted company incorporated on January 9, 2024, with a share capital of $50,000 divided into 500,000,000 Company Shares of par value $0.0001 each. Overview OmnigenicsAI is a pioneering genomics company to be powered by artificial intelligence (“AI”), dedicated to provide secure, precise, and actionable biological data that we believe empowers individuals to take control of their health and enhance their quality of life. Our mission is to revolutionize healthcare by offering a suite of health evaluation services that fully integrate biological, clinical and lifestyle data (“multi -modaldata”) and AI. This innovative approach enhances the accuracy and effectiveness of precision medicine, leading to better health and more informed decisions for our customers. We were founded on and committed to the following principles: • Disrupting the healthcare industry: we are committed to transforming healthcare from impersonal and reactive to personalized and proactive. Through our innovative services, we seek to empower individuals to live healthier lives by providing secure, precise, and actionable biological insights. • Offering a suite of complementary genomic services: we are dedicated to providing a comprehensive suite of services that spans prevention, diagnostics and prognosis, integrating a wide range of multi -modaldata with AI. This approach enables precise, science -drivetools that support individuals with specific health conditions and those seeking to maintain or improve their overall health through preventive care strategies. • Building a strategic consortium: we are actively developing a consortium of laboratories and healthcare providers across the Americas to expand the availability of our prevention and clinical diagnostic products. We aim to launch the consortium following the establishment of our processing hub in Mexico, as it will enable us to provide efficient processing services across the region and develop local markets for genomics services, as well as co -developing